Patents Examined by Shanon A. Foley
-
Patent number: 12290560Abstract: An object of the present invention is to provide an effective vaccine capable of preventing and treating congenital infection with CMV. The vaccine for preventing or treating congenital infection with cytomegalovirus (CMV) according to the present invention comprises a CMV envelope glycoprotein B (gB protein) antigen and a pentamer antigen.Type: GrantFiled: December 6, 2019Date of Patent: May 6, 2025Assignee: KM Biologics Co., Ltd.Inventors: Masaharu Torikai, Hiroaki Mori, Tomohiro Nishimura, Takahiro Katayama, Kohsuke Hazeyama, Miyuki Matsumoto, Hiroyuki Shimizu, Naoki Inoue
-
Patent number: 12290557Abstract: The present invention is directed to novel immunogenic compositions that protect swine from disease caused by porcine epidemic diarrhea virus (PEDV). The present invention is also directed to novel immunogenic compositions that protect swine from disease caused by porcine deltacoronavirus (PDCoV), alone or as combination vaccine to protect against PEDV. The compositions of the invention provide killed viruses whose effectiveness is enhanced by the selection of preferred adjuvants. Novel culture methods are also employed to increase reproducible yield of cultured viruses. Live vaccines are also provided from the Calaf14 PEDV isolate.Type: GrantFiled: February 17, 2021Date of Patent: May 6, 2025Assignee: Zoetis Services LLCInventors: Jacqueline Gayle Marx, John Morgan Hardham, Paul J. Dominowski, Vicki Jon Rapp Gabrielson, Monica Balasch Sanuy, Marta Cabana Sumsi, Laia Plaja Dilmé, Alicia Urniza Hostench, Oscar Romero Galindo
-
Patent number: 12291551Abstract: The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and/or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.Type: GrantFiled: April 8, 2024Date of Patent: May 6, 2025Assignees: Centre National de la Recherche Scientifique (CNRS), Université Paris-SaclayInventors: Aurélie Albertini, Yves Gaudin, Hélène Raux, Laura Belot, Jovan Nikolic
-
Patent number: 12285474Abstract: The invention is based on a platform for vaccination and/or antibody generation. The invention is based on the display of small molecular immunogenic compounds on the coat of variant surface glycoproteins (VSG) on trypanosomes which results in a highly effective immune response when used as a vaccine or in immunization for antibody production. The herein disclosed antigenic particles are applicable for producing antibodies or can be directly used as vaccines for the treatment of various medical conditions. Most preferably the invention relates to the VSG based vaccines specific for dependency causing substances for the treatment of addiction or avoidance of adverse events during drug abuse. Other applications include methods and uses involving the disclosed compounds and compositions for a treatment or prevention of cancer, infectious disease, contagious neurodegenerative diseases, non-communicable disorders (e.g.Type: GrantFiled: October 24, 2019Date of Patent: April 29, 2025Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Fotini Nina Papavasiliou, Hamidreza Hashemi, Gianna Triller, Erec Stebbins, Aubry Miller, Andreas Baumann
-
Patent number: 12285478Abstract: Compositions for prevention of Foot and Mouth Disease (FMD) are provided, comprising an antigen component in the amount equivalent to 0.5-20 ?g FMD virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FMD persistence are also provided.Type: GrantFiled: November 16, 2023Date of Patent: April 29, 2025Assignees: Zoetis Services LLC, United States of America, as represented by the Secretary of AgricultureInventors: Paul Joseph Dominowski, John Morgan Hardham, James Alan Jackson, Cyril Gerard Gay, Luis Leandro Rodriguez, Peter William Krug, Aida Elizabeth Rieder
-
Patent number: 12275758Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.Type: GrantFiled: January 10, 2024Date of Patent: April 15, 2025Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
-
Patent number: 12275771Abstract: Disclosed herein are relaxin immunoglobulin fusion proteins useful for the treatment or prevention of a disease or condition in a subject.Type: GrantFiled: August 26, 2021Date of Patent: April 15, 2025Assignee: THE SCRIPPS RESEARCH INSTITUTEInventors: Feng Wang, Yan Liu, Ying Wang, Guangsen Fu, Peter G. Schultz
-
Patent number: 12274722Abstract: Embodiments relate to a composition comprising a bacteriophage or a mutant thereof and a storage solution, wherein the bacteriophage or the mutant thereof is capable of killing a Gram-positive bacterium comprising Staphylococcus aureus, wherein the composition is stable for at least about a year at 39.2-46.4° F. (4-8° C.).Type: GrantFiled: April 24, 2024Date of Patent: April 15, 2025Assignee: PHAGE TECHNOLOGY CENTER GMBHInventors: Hansjörg Lehnherr, Tatiana Lehnherr-Ilina, Michael Fink
-
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
Patent number: 12270813Abstract: The present invention relates to methods for predicting whether peptides or polypeptides comprising disease specific amino acid modifications, in particular tumor-associated neo-antigens, comprise epitopes, in particular tumor-associated neo-epitopes, which are useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.Type: GrantFiled: June 1, 2018Date of Patent: April 8, 2025Assignee: BioNTech SEInventor: Ugur Sahin -
Patent number: 12269848Abstract: The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and/or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.Type: GrantFiled: April 8, 2024Date of Patent: April 8, 2025Assignees: Centre National de la Recherche Scientifique (CNRS), Université Paris-SaclayInventors: Aurélie Albertini, Yves Gaudin, Hélène Raux, Laura Belot, Jovan Nikolic
-
Patent number: 12268738Abstract: Provided is a liquid formulation of a six combined vaccine containing DPT-IPV-Hib-HBs, in which a HBs antigen is stably adsorbed and retained to an aluminum adjuvant, and PRP as a Hib antigen is stably coupled and retained to a carrier protein.Type: GrantFiled: April 19, 2022Date of Patent: April 8, 2025Assignee: KM BIOLOGICS CO., LTD.Inventors: Shun Yamashita, Tatsuya Shirai, Kazuhiro Daimon, Tomohiro Minoda, Shinji Akasaki, Kanae Ishikawa, Haruna Iwata
-
Patent number: 12264180Abstract: The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and/or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.Type: GrantFiled: April 8, 2024Date of Patent: April 1, 2025Assignees: Centre National de la Recherche Scientifique (CNRS), Université Paris-SaclayInventors: Aurélie Albertini, Yves Gaudin, Hélène Raux, Laura Belot, Jovan Nikolic
-
Patent number: 12257296Abstract: This disclosure relates to chimeric respiratory syncytial virus (RSV), live attenuated vaccine and immunogenic compositions, and methods of use. In certain embodiments, the chimeric respiratory syncytial virus has a mutated gene pattern encoding an RSV F protein having M at position 79, R at position 191, K at position 357, and/or Y at position 371.Type: GrantFiled: January 14, 2022Date of Patent: March 25, 2025Assignee: Emory UniversityInventors: Martin L. Moore, Christina Rostad
-
Patent number: 12247051Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.Type: GrantFiled: November 21, 2023Date of Patent: March 11, 2025Inventors: Luis Alejandro Hernandez, Christine Margaret Muehlenthaler, Eric Martin Vaughn, Gregory Haiwick
-
Patent number: 12247977Abstract: The present disclosure provides methods for determining the presence or absence of and/or the etiology of an acute respiratory viral infection in a subject, as well as methods of treating the subject based on the determination, by measuring on a platform the expression levels of a pre-defined set of gene products.Type: GrantFiled: February 2, 2018Date of Patent: March 11, 2025Assignee: Duke UniversityInventors: Thomas W. Burke, Ricardo Henao Giraldo, Erik Soderblom, Joseph Lucas, Christopher W. Woods, Geoffrey S. Ginsburg
-
Patent number: 12239705Abstract: This invention relates to dermatology and to treatments of infectious skin disease.Type: GrantFiled: April 21, 2021Date of Patent: March 4, 2025Assignee: University of RochesterInventors: Matthew G. Brewer, Lisa A. Beck, Brian M. Ward, Benjamin L. Miller
-
Patent number: 12239698Abstract: This disclosure provides HIV immunogens and use thereof for generating an immune response in a subject. Also disclosed is a method of isolating anti-HIV antibodies and use thereof. This disclosure further provides a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject using the disclosed HIV immunogens and/or antibodies.Type: GrantFiled: November 27, 2019Date of Patent: March 4, 2025Assignees: The Rockefeller University, California Institute of TechnologyInventors: Michel Nussenzweig, Pamela J. Bjorkman, Amelia Escolano, Harry Gristick
-
Patent number: 12239701Abstract: Provided herein are a respiratory syncytial virus (RSV) vaccine composition including a messenger ribonucleic acid (mRNA) including an open reading frame (ORF) encoding RSV mutant F B strain protein, and optionally a mRNA including an ORF encoding RSV mutant F A strain protein, and a method of inducing immune response against RSV by administering an effective amount of the RSV vaccine composition to a subject in need thereof. Provided herein are also a respiratory syncytial virus (RSV) and human metapneumovirus virus (hMPV) vaccine composition including a mRNA including an ORF encoding RSV mutant F A strain protein, a mRNA including an ORF encoding RSV mutant F B strain protein, and a mRNA including an ORF encoding hMPV F protein, and a method of inducing immune response against RSV and hMPV by administering an effective amount of the RSV and hMPV vaccine composition to a subject in need thereof.Type: GrantFiled: December 22, 2023Date of Patent: March 4, 2025Assignee: Vernagen, LLCInventors: Baek Kim, Jack Yoon, David Pak
-
Patent number: 12235269Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Antibodies produced from an immune response against SARS-CoV-2 are used to analyze prior exposure to the virus. The present invention provides methods for detecting antibodies in response to SARS-CoV-2 infection in a single multiplex immunoassay.Type: GrantFiled: July 29, 2021Date of Patent: February 25, 2025Assignee: Pictor LimitedInventors: Sandeep Kumar Vashist, Lionel Gilles Guiffo Djoko, Bhavesh Govind
-
Patent number: 12234265Abstract: The disclosure relates to stable RSV F proteins and immunogenic compositions containing the same, as well as methods of using the immunogenic compositions and compositions comprising the RSV F proteins.Type: GrantFiled: December 20, 2022Date of Patent: February 25, 2025Assignee: Merck Sharp & Dohme LLCInventors: Lan Zhang, Arthur Fridman, Eberhard Durr, Andrew Bett